2,4,5-trifluoro-3-methylbenzamide | 112822-86-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4,5-trifluoro-3-methylbenzamide
• 英文别名: 2,4,5-trifluoro-3-methylbenzoyl chloride
• CAS: 112822-86-3
• 化学式: C₈H₄ClF₃O
• 分子量: 208.567
• InChiKey: AAZLABCSWUPJBU-UHFFFAOYSA-N

物化性质

• 沸点：
  90-92 °C(Press: 40 Torr)
• 密度：
  1.440±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4,5-trifluoro-3-methylbenzamide 在 氨 作用下， 以 四氢呋喃 为溶剂， 以300 g的产率得到2,4,5-trifluoro-3-methylbenzamide
  参考文献：
  名称：

  The Preparation of Two, Preclinical Amino-quinazolinediones as Antibacterial Agents

  摘要：

  This paper describes the synthesis of two amino-quinazolinediones which are potent gyrase/topoisomerase inhibitors and useful as antibacterial agents. The early scale-up work to prepare a chiral side chain on multigram scale and two different amino-quinazolinedione cores is detailed. The enabling synthesis for the side chain employed a previously reported Michael addition of MeNO2 to an enantiomerically enriched delta-amino-enoate and a two-step de-oxygenation of a lactam. Key synthetic steps for core preparation and completion of the amino-quinazolinediones include dianion-promoted cyclization via intramolecular, nucleophilic aromatic substitution, electrophilic amination, nucleophilic aromatic substitution of the side chain to the core, deprotection and isolation of the hydrochloride salt in acceptable yield.

  DOI：

  10.1021/op7000639
• 作为产物：
  描述：

  2,4,5-三氟苯甲酸 在 草酰氯 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.5h， 生成 2,4,5-trifluoro-3-methylbenzamide
  参考文献：
  名称：

  The Preparation of Two, Preclinical Amino-quinazolinediones as Antibacterial Agents

  摘要：

  This paper describes the synthesis of two amino-quinazolinediones which are potent gyrase/topoisomerase inhibitors and useful as antibacterial agents. The early scale-up work to prepare a chiral side chain on multigram scale and two different amino-quinazolinedione cores is detailed. The enabling synthesis for the side chain employed a previously reported Michael addition of MeNO2 to an enantiomerically enriched delta-amino-enoate and a two-step de-oxygenation of a lactam. Key synthetic steps for core preparation and completion of the amino-quinazolinediones include dianion-promoted cyclization via intramolecular, nucleophilic aromatic substitution, electrophilic amination, nucleophilic aromatic substitution of the side chain to the core, deprotection and isolation of the hydrochloride salt in acceptable yield.

  DOI：

  10.1021/op7000639

文献信息

• THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS
  申请人：Gopalsamy Ariamala

  公开号：US20090118276A1

  公开（公告）日：2009-05-07

  The present invention relates to compounds of formula la: and pharmaceutically acceptable salts thereof. The thieno[3,2-d]pyrimidine, thieno[2,3-d]pyrimidine, thieno[3,2-b]pyridine, thieno[2,3-b]pyridine, and pyrrolo[2,3-d]pyrimidine compounds selectively inhibit B-Raf kinase activity and are useful for treating disorders mediated by B-Raf kinase, and for the treatment of cancer.

  本发明涉及下式(Ia)的化合物： 以及药用可接受的盐。这些噻吩[3,2-d]嘧啶、噻吩[2,3-d]嘧啶、噻吩[3,2-b]吡啶、噻吩[2,3-b]吡啶和吡咯[2,3-d]嘧啶化合物选择性地抑制B-Raf激酶活性，并可用于治疗由B-Raf激酶介导的疾病，以及用于治疗癌症。
• [EN] SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF<br/>[FR] CARBOXAMIDES DE N-PHÉNYL-BIPYRROLIDINE SUBSTITUÉS ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI AVENTIS

  公开号：WO2009052065A1

  公开（公告）日：2009-04-23

  The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I), Wherein R, R1, R2, R3 and R4 are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also discloses methods of preparation of substituted N-phenyl-bipyrrolidine carboxamides and intermediates therefor.

  本发明公开并声明了一系列式(I)的取代N-苯基-双吡咯烷羧酰胺，其中R、R1、R2、R3和R4如本文所述。更具体地说，本发明的化合物是H3受体调节剂，因此在制药方面特别有用，尤其是在治疗和/或预防通过H3受体调节的各种疾病，包括与中枢神经系统相关的疾病。此外，本发明还公开了取代N-苯基-双吡咯烷羧酰胺及其中间体的制备方法。
• [EN] NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE<br/>[FR] NOUVEAUX DERIVES DE PHENYLAMINOPYRIMIDINE EN TANT QU'INHIBITEURS DE BCR-ABL KINASE
  申请人：NATCO PHARMA LTD

  公开号：WO2006027795A1

  公开（公告）日：2006-03-16

  The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I). The novel compounds of the formula 1 can be used in the therapy of Chronic Myeloid Leukemia (CML). Since the IC₅₀; 191 values of these molecules are in the range 0.1 to 10.0 nm, these novel compounds are potentially useful for the treatment of CML.

  本发明涉及用于制备新型苯基氨基嘧啶衍生物的中间体，新型苯基氨基嘧啶衍生物。含有新型苯基氨基嘧啶衍生物的药物组合物及其制备方法。本发明特别涉及一般式（I）的新型苯基嘧啶胺衍生物。一般式1的新化合物可用于慢性髓细胞白血病（CML）的治疗。由于这些分子的IC₅₀；191值在0.1至10.0 nm范围内，这些新型化合物有望用于治疗CML。
• [EN] 1H-1,8- NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS<br/>[FR] 1H-1,8-NAPHTHYRIDIN-2 ONES UTILISÉES COMME COMPOSÉS ANTI PROLIFÉRATIFS
  申请人：NATCO PHARMA LTD

  公开号：WO2015186137A1

  公开（公告）日：2015-12-10

  The present invention relates to novel antiproliferative1H-1, 8-naphthyridin-2-ones of the general formula (I) or pharmaceutically acceptable salts thereof: In which the variable groups are as defined herein, and their preparation and use in therapeutic treatment of disorders related to inhibition of tyrosine kinases in warm blooded animals. The compounds can overcome imatinib induced drug resistance.

  本发明涉及一种新型抗增殖1H-1,8-萘啶并吡啶酮化合物，其通式为(I)，或其在药学上可接受的盐：其中变量基团如本文所定义，并且它们的制备和在治疗温血动物中与酪氨酸激酶抑制相关的疾病的治疗中的用途。这些化合物可以克服伊马替尼诱导的药物耐药性。
• Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them
  申请人：SANOFI

  公开号：US20140330009A1

  公开（公告）日：2014-11-06

  The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.

  这项发明涉及到式(I)的取代4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶类化合物，它们作为药物的用途，以及包含它们的药物制剂。式(I)的化合物作用于TASK-1钾通道。这些化合物特别适用于治疗或预防心房心律失常，例如心房颤动（AF）或心房扑动。